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Purpose: Hypercholesterolemia is a critical problem in patients with carotid atherosclerosis. 
The adequacy of attention to lipid risk factors in patients with carotid stenosis awaiting 
carotid endarterectomy (CEA) has rarely been studied. We also assessed patient awareness of 
hypercholesterolemia and carotid plaque morphology.
Methods: A prospective study was conducted of 141 consecutive patients admitted electively 
for CEA. Each patient’s medical history was taken. Plasma cholesterol concentrations were 
determined. Plaque histology was scored according to American Heart Association criteria and 
their modiﬁ  cation.
Results: Of patients who were aware of their hypercholesterolemia and who were receiving 
treatment, 28.6% had total cholesterol levels 5 mmol/L. Among those patients who had 
been told that they had no problem with hypercholesterolemia, 32.5% had plasma cholesterol 
concentrations 5 mmol/L. Among those patients who had never had their plasma cholesterol 
measured, 48.4% had total cholesterol levels 5 mmol/L. Patients in this last group tended 
to have more severe types of plaque pathology than those in other groups (12.9% plaque 
rupture).
Conclusions: Hypercholesterolemia does not seem to be well managed in patients 
awaiting CEA.
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Introduction
Hypercholesterolemia is one of the most important risk factors in the development 
and progression of atherosclerosis, the major cause of vascular disease (Castelli 
1984). Hypercholesterolemia has also been reported to be associated with myocardial 
infarction (Kannel et al 1971). It can be modiﬁ  ed by diet or drugs. Indeed a number of 
randomized controlled trials (RCTs) of lipid-lowering medications (both primary and 
secondary prevention) have shown clear clinical beneﬁ  t of the effects on cardiovascular 
events (Shepherd et al 1995; Sacks et al 1996; HPS 2002). This beneﬁ  t has been 
shown in both short and long term results. The West of Scotland Coronary Prevention 
Study (WOSCOPS) was an RCT comparing pravastatin with placebo in men with 
hypercholesterolemia, and no history of myocardial infarction, with an average follow-
up of approximately 5 years (Barringer 1997). The combined outcome of death from 
deﬁ  nite coronary heart disease or deﬁ  nite nonfatal myocardial infarction was reduced 
from 7.9% in the control group to 5.5% (p  0.001) in the pravastatin group (Ford et al 
2007). In the 10-year follow-up after this RCT was completed, 38.7% of the original 
statin group and 35.2% of the original placebo group were being treated with a statin. The 
risk of death from coronary heart disease or nonfatal myocardial infarction was 10.3% 
in the placebo group and 8.6% in the pravastatin group (p = 0.02) (Ford et al 2007). Vascular Health and Risk Management 2008:4(6) 1260
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Many protocols and guidelines have therefore stressed the 
importance of detection and control of hyperlipidemia, 
especially hypercholesterolemia, in patients with atheroscle-
rosis (JBS1 1998; NCEP 2001; Stroke Council 2004; Grundy 
et al 2004). Patients with coronary artery disease (CAD) are 
likely to have their hypercholesterolemia treated, but many 
studies have found that physicians still do not fully acknowl-
edge the importance of treating hypercholesterolemia in all 
patients with atherosclerosis (Cohen et al 1991; Rajagopalan 
et al 2007).
The Heart Protection Study, a large RCT, compared the 
5-year risk of vascular events in patients with a high risk of 
coronary death receiving either simvastatin or placebo (HPS 
2002). In a study subgroup, patients with cerebrovascular 
disease who were taking statins, including those who 
had undergone carotid endarterectomy (CEA), also had a 
signiﬁ  cantly lower risk of major vascular events (combined 
rate of coronary events, strokes and re-vascularizations 
24.7%) than those in the control group (29.8%). Similarly, 
recent trials in patients with recent stroke or TIA and no known 
coronary heart disease showed that 80 mg of atorvastatin per 
day reduced the overall incidence of strokes and cardiovas-
cular events (Amarenco et al 2006). These results indicate 
that patients for whom CEA is indicated, should survive 
longer or have less chance of major vascular events if their 
hypercholesterolemia is managed properly. Moreover there 
is compelling evidence that hypercholesterolemia is a risk 
factor for carotid re-stenosis after CEA (Das et al 1985; 
Rapp et al 1987).
Despite the overwhelming evidence of the risk of 
hypercholesterolemia in patients with peripheral vascular 
disease, including carotid artery stenosis (CAS), to our 
knowledge no study has examined the management of 
hyperlipidemia and carotid plaque morphology. The 
ﬁ  rst objective of this study was to examine the incidence 
of hypercholesterolemia among patients awaiting CEA 
and to relate this incidence to patient awareness of their 
hypercholesterolemia. A second objective was to study the 
relationship of patient awareness of hypercholesterolemia and 
carotid plaque characteristics determined by morphological 
examination.
Methods
The study was approved by our Research Ethics Committee, 
and written informed consent was obtained from the patients 
recruited. From 1998 to 2001, 141 consecutive patients 
were included prospectively. Medical histories were taken, 
including patient awareness of hypercholesterolemia. Patient 
records including drug charts were checked for use of 
any lipid-lowering medication. On the pre-operative visit, 
fasting venous blood samples were taken and stored in 
vacutainer tubes containing 0.12 mL of 15% EDTA. Plasma 
was prepared by centrifugation at 1500 g for 10 minutes 
and stored at –80 ºC. Concentrations of total plasma 
cholesterol were determined using a commercially available, 
enzyme-based diagnostic kit.
The carotid plaques removed at surgery were cleaned with 
saline. Serial transverse 2 mm sections were taken. These 
sections were labeled alphabetically starting from the distal 
end of the internal carotid artery and ending at the common 
carotid artery. Parafﬁ  n-embedded sections were stained with 
hemoxylin and eosin. The section closest to the bifurcation 
was classiﬁ  ed according to the guidelines published by 
the American Heart Association (AHA) system (the Stary 
system) (Stary et al 1995), and a proposed modiﬁ  cation of 
this system (Virmani et al 2000).
Analysis
Patient awareness of hypercholesterolemia was classiﬁ  ed 
in three ways. Group 1 patients were those who were aware 
of an abnormality and who had been given treatment or 
advice. Group 2 patients claimed that their doctors had said 
that their blood tests were normal. Group 3 patients were 
unaware of any testing of blood lipids. At the time of this 
study the AHA guidelines recommended that for patients 
with major atherosclerotic disease, including patients who 
had undergone CEA, plasma total cholesterol should be less 
than 5 mmol/L (JBS1 1998). Patients in the three groups were 
classiﬁ  ed into two further sub-groups: those with plasma 
cholesterol concentrations greater than or equal to 5 mmol/L 
and those with plasma cholesterol concentrations less than 
5 mmol/L. These three groups were also classiﬁ  ed by carotid 
plaque pathology according to AHA and modiﬁ  ed AHA 
score. All data are described in percentages. The comparison 
between groups was determined by chi-squared test. P  0.05 
was considered to indicate statistical signiﬁ  cance.
Results
Eighty-one males and 60 females with a mean age of 69.4 
years were included; 41.1% of these patients had a history 
of either angina or myocardial infarction and 9.2% had 
previously undergone contralateral CEA. The mean blood 
pressure and the percentage of current smokers were higher 
in Group 3 than in the other two groups (Table 1). In Group 
1, 53% of patients were on statin medication, with a median 
duration of 3.5 years.Vascular Health and Risk Management 2008:4(6) 1261
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Of 141 patients (34.0%) awaiting carotid endarterectomy, 
48 had levels of total cholesterol greater than or equal 
to 5 mmol/L (Table 2). Because their physician had 
informed them of it, 70 patients were aware of their 
hypercholesterolemia (Group 1). Twenty of these 
70 patients (28.6%) still had total cholesterol levels greater 
than this. Interestingly, in Group 1, 33 patients had histories 
of ischemic heart disease and nine patients (12.9%) in this 
subgroup still had total cholesterol levels greater than 
5 mmol/L. Because their physicians had informed them 
that they did not have hypercholesterolemia, 40 patients 
denied having this condition (Group 2); 13 patients in this 
group (32.5%) had levels of total cholesterol 5 mmol/L. 
Thirty-one of 141 patients (22%) had never had their 
cholesterol levels checked or were unaware of any previous 
cholesterol tests (Group 3). Fifteen patients in this group 
(48.4%) had total cholesterol levels 5.0 mmol/L.
Carotid plaque morphology in Group 3 tended to be more 
severe (according to AHA classiﬁ  cation) than in the other 
groups (Table 3). The combined percentages of Type V and 
Table 1 Patient characteristics at study entry
Group 1 N = 70 Group 2 N = 40 Group 3 N = 31
Gender: men (%) 37 (52.9) 22 (55.0) 22 (71.0)
Mean age (years, mean (SD)) 68.4 (7.7) 73.1 (8.3) 70.3 (9.0)
Body mass index (kg/m2, 
mean (SD))
26.7 (4.2) 25.6 (3.3) 25.8 (3.9)
Clinical history (%)
 Hypertension
 Diabetes
 Angina  pectoralis
 Myocardial  infarction
57 (81.4)
18 (25.7)
12 (17.1)
10 (14.3)
23 (57.5)
6 (15.0)
4 (10.0)
2 (5.0)
23 (74.2)
8 (25.8)
5 (16.1)
4 (12.9)
Smoking status (%)
 Current  smokers
 Ex-smokers
8 (11.4)
51 (72.9)
5 (12.5)
26 (65.0)
5 (16.1)
19 (61.3)
Mean arterial blood pressure 
(mmHg, mean (SD))
 Systolic
 Diastolic
161.1 (24.5)
84.5 (14.3)
163.3 (26.6)
85.9 (15.0)
167.3 (25.9)
87.5 (13.3)
Drug use (%)
 Aspirin
 Beta-blocker
 ACE  inhibitor
 Nitrates
  Calcium channel blocker
 Fibrates
 Statin
 Insulin
 Oral  antidiabetics
70 (100.0)
16 (22.9)
14 (20.0)
12 (17.1)
25 (35.7)
2 (2.9)
37 (52.9)
4 (5.7)
8 (11.4)
40 (100.0)
9 (22.5)
8 (20.0)
7 (17.5)
14 (35.0)
0
0
2 (5.0)
5 (12.5)
31 (100.0)
8 (25.8)
7 (22.6)
6 (19.4)
11 (35.5)
0
0
2 (6.5)
4 (12.9)
Notes: Group 1 patients were those who were aware of an abnormality and had been given treatment or advice. Group 2 patients claimed that their doctors had said that 
their blood tests were normal. Group 3 patients were unaware of any previous testing of blood lipids.
Abbreviations: ACE, angiotensin converting enzyme; N, total; SD, standard deviation.
Table 2 The relationship between plasma total cholesterol concentration (5 mmol/L versus 5 mmol/L) and the awareness of 
patient of hypercholesterolemia (n (%))
Plasma cholesterol Group 1 N = 70 Group 2 N = 40 Group 3 N = 31 p value
5 mmol/L 20 (28.6) 13 (32.5) 15 (48.4) 0.148
5 mmol/L 50 (71.4) 27 (67.5) 16 (51.6)
Abbreviation: N, total.Vascular Health and Risk Management 2008:4(6) 1262
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VI in Groups 1, 2, and 3 were 35.7%, 25.0%, and 41.9% 
respectively. Similarly patients in Group 3 had a higher 
percentage of plaque rupture than the other groups. Patients 
with plasma cholesterol 5 mmol/L tended to have a higher 
grade of plaque morphology than those with lower plasma 
cholesterol (Table 4). However these trends did not reach 
statistical signiﬁ  cance. There was no statistically signiﬁ  cant 
perioperative complication after CEA among three groups 
(Table 5).
Discussion
Despite overwhelming evidence demonstrating the 
benefits of lipid lowering therapies in vascular patients, 
in clinical practice hyperlipidemia is poorly managed 
(Aspry et al 1995). Mismanagement is evident in 
the current study, because 22% of these patients had 
apparently never had their lipid profiles checked or were 
unaware of any previous plasma lipid tests. Similarly, 
Burns and colleagues found that 47% of patients with 
peripheral arterial disease had never had a cholesterol 
measurement (Burns et al 2002). Perhaps even more dis-
appointingly, around one third of patients who had been 
treated for hypercholesterolemia (Group 1) still had total 
cholesterol levels higher than the recommended level 
(5 mmol/L). Similarly, a cross-sectional analysis by 
Rajagopalan et al of 70,194 UK patients who had begun 
lipid modifying therapy in 2005, found that 21.8% of 
patients with evidence of atherosclerosis had plasma 
Table 3 Relationship between patient awareness of hypercholesterolemia and carotid plaque morphology (% of patients)
Group 1 N = 70 Group 2 N = 40 Group 3 N = 31 p value
AHA classiﬁ  cation type
 III 0 0 3.2 0.371
 IV 64.3 75.0 54.8
 Va 21.4 17.5 22.6
 Vb 4.3 5.0 3.2
 VI 10.0 2.5 16.1
Modiﬁ  ed AHA classiﬁ  cation type
  Pathological intimal thickening 8.6 2.5 6.5 0.367
  Fibrous cap atheroma 58.6 72.5 51.6
 Thin  ﬁ  brous cap atheroma 22.9 17.5 25.8
 Erosion 1.4 2.5 0
 Plaque  rupture 4.3 0 12.9
Abbreviations: AHA, American Heart Association; N, total.
Table 4 Relationship between plasma cholesterol and carotid plaque morphology (% of patients)
Cholesterol level 5 mmol/L N = 48 Cholesterol level 5 mmol/L N = 93 p value
AHA classiﬁ  cation type
 III 0 1.1 0.596
 IV 58.3 68.6
 Va 22.9 19.4
 Vb 6.3 3.2
 VI 12.5 7.5
Modiﬁ  ed AHA classiﬁ  cation type
  Pathological intimal thickening 8.3 5.4 0.577
  Fibrous cap atheroma 50.0 66.7
 Thin  ﬁ  brous cap atheroma 25.0 20.4
 Erosion 2.1 1.1
 Plaque  rupture 8.3 3.2
Abbreviations: AHA, American Heart Association; N, total.Vascular Health and Risk Management 2008:4(6) 1263
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cholesterol 5 mmol/L. This result is comparable with 
the data from Group 1 in our study.
There were several possible impediments to the 
guidelines (JBS1 1998). Many physicians did not want to 
follow the guidelines partly due to knowledge deﬁ  ciency or 
a negative attitude toward the guidelines (Frolkis et al 1998). 
Also many general practitioners reported that their concern 
about patient ability to understand and adhere to treatment 
recommendations, increased workloads, and medication 
costs (Kedward and Dakin 2003). Another reason for this 
ignorance is that some clinicians believe that once a patient 
has severe carotid stenosis and is waiting for carotid surgery, 
lipid-lowering drugs are no longer beneﬁ  cial. In other words, 
it is already too late to treat a severely stenotic lesion. While 
it is true that a severely stenotic lesion is unlikely to regress 
in the short term, in many trials statins have reduced the 
incidence of myocardial infarction (Ford et al 2007), the 
main cause of death peri-operatively and long-term after CEA 
(Musser et al 1994; Kerdiles et al 1997). Nevertheless, this 
effect was not demonstrated (Table 5) in our study perhaps 
because of the small sample size.
To achieve a high long-term survival rate for patients 
undergoing CEA, adequate management of hypercholes-
terolemia is of paramount important because myocardial 
infarction is the most common cause of death in these patients 
(Kerdiles et al 1997). Statin treatment has been shown to be 
cost effective compared with other medical interventions, and 
cost effectiveness is related to the efﬁ  cacy of the drug and the 
risk of cardiovascular disease (Pickin et al 1999). Consensus 
health panels, including the Joint British Societies, have 
established increasingly stringent cholesterol goals, such 
as a total cholesterol goal of 4.0 mmol/L (JBS2 2005). 
In view of the increasing amount of data on the beneﬁ  t of 
statins, the American Heart Association issued advice in 
2004 suggesting that clinicians should consider initiating 
statin therapy in the hospital for all patients who had suf-
fered stroke of atherosclerotic origin (Das et al 1985; Stroke 
Council 2004).
Our ﬁ  ndings raise even more concern when the plaque 
histological grading results are considered. We found that 
patients who had either never had their lipid proﬁ  les checked 
(Group 3) (Table 3) or had hypercholesterolemia (Table 4) 
seemed to be more likely to have unstable carotid plaques 
than those in the other two groups. For example, patients 
with hypercholesterolemia, around 8.3% of all patients, 
had histological features of plaque rupture, and a quarter of 
these patients had thin ﬁ  brous cap atheroma, which is a high 
risk plaque for rupture. A study found that an unhealthy life 
style such as poorly controlled blood pressure, smoking, 
physical inactivity, and alcoholic consumption correlate well 
with lipid proﬁ  le abnormality (Mirjanic-Azaric et al 2006). 
We found that patients in Group 3 had higher systolic and 
diastolic blood pressure than patients in the other two groups. 
Similarly the percentage of patients currently smoking 
was higher in Group 3 than in other groups. Perhaps those 
patients with hypercholesterolemia and those in Group 3 have 
unhealthy lifestyles, which cause active plaque rather than 
other factors. In other words, poor cholesterol management 
seemed to reﬂ  ect poor management of other vascular risk 
factors. Active plaques in one vascular bed appear to be 
associated with active plaques in other remote vascular 
beds. Rothwell et al (2000) studied the angiographic data 
from the European Carotid Surgery Trial. They found that 
carotid plaque surface irregularities, believed to arise from 
plaque rupture and ulceration, predicted an increased risk 
of arterial disease in other vascular beds including coronary 
events. Therefore patients who are unaware of any previous 
cholesterol test have a higher risk of coronary events than 
those in other groups.
Limitations
There are some limitations to this study. First, only the total 
cholesterol level was used to demonstrate hyperlipidemia, 
although high serum low-density lipoprotein (LDL) 
cholesterol levels may be a better measure of lipid abnormality. 
When we designed this study however, serum cholesterol was 
far more widely recognised by patients than serum LDL. Sec-
ondly, total cholesterol 5 mmol/L was the recommended 
level for hypercholesterolemia (JBS1 1998) used during the 
study period, which is a less stringent cholesterol goal than 
current criteria (total cholesterol 4 mmol/L) (JBS2 2005). 
One might think that patients are probably much better treated 
nowadays. However, in 2007, a study reported that most 
UK patients (approximately 73%) would not have achieved 
the goals recently established by the Joint British Societies 
(Rajagopalan et al 2007). In this study, other atherosclerotic 
risk factors such as smoking and hypertension were not 
considered in detail, although they are part of atherosclerotic 
Table 5 Peri-operative complications following carotid endarter-
ectomy (%)
Postoperative complication Group 1 Group 2 Group 3
Myocardial infarction 1 (1.5) 0 0
Stroke 2 (2.9) 1 (2.6) 1 (3.4)
Death 1 (1.5%) 0 0Vascular Health and Risk Management 2008:4(6) 1264
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risk factor management. Lastly, our sample size might be too 
small for multivariate analysis.
Conclusions
This study suggests that treatment of hypercholesterolemia in 
patients for whom CEA is indicated is inadequate in clinical 
practice, despite much evidence of the beneﬁ  ts of lowering 
lipid levels. A great deal more effort should be directed at 
managing blood cholesterol in patients with carotid artery 
stenosis. These ﬁ  ndings support the need for improved 
education of clinicians and patients in the management of 
cholesterol levels in patients with vascular disease.
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